Objective: To evaluate the regulation of acute‐phase serum amyloid A (A‐SAA) production in inflamed synovial tissue, and to elucidate a possible pathophysiologic role in the induction of matrix metalloproteinase (MMP) release by fibroblast‐like synoviocytes (FLS).Methods: Synovial tissue samples were obtained by arthroscopic biopsy from the knee joints of patients with inflammatory arthritis. Primary cultures of FLS from patients with rheumatoid arthritis (RA), psoriatic arthritis, sarcoid arthritis, and undifferentiated arthritis were established. Total RNA was extracted from FLS and analyzed by reverse transcription–polymerase chain reaction (PCR) using specific primers for A‐SAA and formyl peptide receptor–like 1 (FPRL1), an A‐SAA receptor. Southern blot analysis confirmed the PCR products generated. Immunohistochemical analysis demonstrated the expression of A‐SAA protein production by several synovial cell populations, and immunofluorescence analysis confirmed A‐SAA colocalization with the macrophage marker CD68. Primary FLS cultures stimulated with recombinant human A‐SAA resulted in dose‐dependent MMP‐1 and MMP‐3 production, as measured by an enzyme‐linked immunosorbent assay.Results: A‐SAA messenger RNA (mRNA) and FPRL1 mRNA were present in FLS, macrophages, and endothelial cells isolated from the synovial tissue of patients with RA and other categories of inflammatory arthritis. A‐SAA expression was regulated by proinflammatory cytokines and occurred in association with FPRL1 expression in FLS and endothelial cells, which is consistent with a biologic role at the sites of inflammation. Recombinant human A‐SAA induced both MMP‐1 and MMP‐3 secretion by FLS. The mean fold increases in A‐SAA–induced MMP‐1 and MMP‐3 production were 2.6 and 10.6, respectively, compared with 7.6‐fold and 41.9‐fold increases in interleukin‐1β–induced MMP‐1 and MMP‐3 production.Conclusion: The up‐regulation of the A‐SAA and FPRL1 genes in inflamed synovial tissue suggests an important role in the pathophysiology of inflammatory arthritis. A‐SAA induces the production of MMPs. Therapeutic targeting of A‐SAA, or FPRL1, may modulate pathophysiologic pathways that are associated with matrix degradation in patients with RA and other forms of progressive inflammatory arthritis.

Objective: To examine the role of the acute‐phase protein serum amyloid A (A‐SAA) in regulating cell adhesion molecule expression, leukocyte recruitment, and angiogenesis in rheumatoid arthritis (RA).Methods: Intercellular adhesion molecule 1 (ICAM‐1), vascular cell adhesion molecule 1 (VCAM‐1), and matrix metalloproteinase 1 (MMP‐1) expression was examined in RA fibroblast‐like synoviocytes (FLS) and human microvascular endothelial cells (HMVECs) using flow cytometry and enzyme‐linked immunosorbent assay techniques. Peripheral blood mononuclear cell (PBMC) adhesion to FLS/HMVECs was determined by flow cytometry. Angiogenesis was examined using a Boyden chemotaxis chamber and Matrigel tubule formation. NF‐κB/IκBα mediation of the effects of A‐SAA was investigated using a specific NF‐κB inhibitor and Western blotting.Results: A‐SAA significantly enhanced the time‐ and dose‐dependent expression of ICAM‐1 and VCAM‐1 as effectively as interleukin‐1β/tumor necrosis factor α. A‐SAA promoted the adhesion of PBMCs to FLS and HMVECs. In addition, A‐SAA at 10 μg/ml and 50 μg/ml significantly increased endothelial cell tube formation by 69% and 207%, respectively. At 50 μg/ml and 100 μg/ml, A‐SAA increased HMVEC migration by 188 ± 54% and 296 ± 71%, respectively (mean ± SEM). A‐SAA–induced expression of VCAM‐1, ICAM‐1, and MMP‐1 was down‐regulated by NF‐κB inhibition. Furthermore, A‐SAA induced IκBα degradation and NF‐κB translocation, suggesting that its proinflammatory effects are mediated in part by NF‐κB signaling.Conclusion: Our findings demonstrate the ability of A‐SAA to induce adhesion molecule expression, angiogenesis, and matrix degradation, mechanisms that are mediated by NF‐κB. Targeting A‐SAA and its signaling pathways may represent a new therapeutic approach in the treatment of RA.

Acute-phase serum amyloid A (A-SAA) is a major component of the acute-phase response. A sustained acute-phase response in rheumatoid arthritis (RA) is associated with increased joint damage. A-SAA mRNA expression was confirmed in all samples obtained from patients with RA, but not in normal synovium. A-SAA mRNA expression was also demonstrated in cultured RA synoviocytes. A-SAA protein was identified in the supernatants of primary synoviocyte cultures, and its expression colocalized with sites of macrophage accumulation and with some vascular endothelial cells. It is concluded that A-SAA is produced by inflamed RA synovial tissue. The known association between the acute-phase response and progressive joint damage may be the direct result of synovial A-SAA-induced effects on cartilage degradation.

Osteoarthritis (OA) is a multifactorial chronic musculoskeletal disorder characterised by cartilage degradation, synovial inflammation, and subchondral bone remodelling. Conventional diagnostic modalities, including radiographic imaging and symptom-based assessments, primarily detect disease in its later stages, limiting the potential for timely intervention. Inflammatory biomarkers, particularly Interleukin-6 (IL-6), Tumour Necrosis Factor-alpha (TNF-α), and Myeloperoxidase (MPO), have emerged as biologically relevant indicators of disease activity, with potential applications as companion diagnostics in precision medicine. This review examines the diagnostic and prognostic relevance of IL-6, TNF-α, and MPO in OA, focusing on their mechanistic roles in inflammation and joint degeneration, particularly through the activity of fibroblast-like synoviocytes (FLSs). The influence of sample type (serum, plasma, synovial fluid) and analytical performance, including enzyme-linked immunosorbent assay (ELISA), is discussed in the context of biomarker detectability. Advanced statistical and computational methodologies, including rank-based analysis of covariance (ANCOVA), discriminant function analysis (DFA), and Cox proportional hazards modelling, are explored for their capacity to validate biomarker associations, adjust for demographic variability, and stratify patient risk. Further, the utility of synthetic data generation, hierarchical clustering, and dimensionality reduction techniques (e.g., t-distributed stochastic neighbour embedding) in addressing inter-individual variability and enhancing model generalisability is also examined. Collectively, this synthesis supports the integration of biomarker profiling with advanced analytical modelling to improve early OA detection, enable patient-specific classification, and inform the development of targeted therapeutic strategies.

Objective: This study employed advanced biostatistical methods to investigate Interleukin-6 (IL-6), Tumour Necrosis Factor Alpha (TNF-α), and Myeloperoxidase (MPO) levels in serum and plasma samples from patients with severe osteoarthritis (OA) compared to volunteers. The primary aim was to evaluate the diagnostic potential of these biomarkers and address statistical challenges, including non-normal data distribution and non-aged-matched groups. Design: Using Enzyme-Linked Immunosorbent Assays (ELISAs), IL-6, TNF-α, and MPO concentrations were analysed in 58 OA patients and 28 volunteers. Statistical analyses included Shapiro–Wilk tests to assess normality, a Mann–Whitney U (MWU) test to compare biomarker levels, and sensitivity analyses using Rank-based ANCOVA, and regression models were used to address non-normal data distributions and to validate the findings under adjustments for age and gender. Levene’s test was used to evaluate the homogeneity of variables. Results: Serum TNF-α and plasma MPO were significantly higher in OA patients than in volunteers (p < 0.05), while IL-6 levels were non-significant (p = 0.160). MWU tests confirmed significant differences for TNF-α (p = 0.045) and MPO (p = 0.0001). Sensitivity analysis using Rank-based ANCOVA and regression models confirmed the robustness of these biomarkers, with TNF-α (p = 0.037) and MPO (p = 0.0099) retaining statistical significance after adjusting for covariates. IL-6 remained non-significant across all analyses. Conclusions: TNF-α and MPO emerged as statistically robust biomarkers for severe OA, with the serum samples better reflecting inflammation than plasma. These findings underscore the importance of using advanced biostatistical methods such as Rank-based ANCOVA and regression to validate biomarkers, particularly in heterogenous datasets. Future research should incorporate larger, more diverse cohorts and detailed demographic profiling to explore the early diagnostic potential of these biomarkers and further understand OA progression.

Objectives: This study investigated the inflammatory responses of fibroblast-like synoviocytes (FLS) isolated from osteoarthritis (OA) patients, stimulated with lipopolysaccharide (LPS) and interleukin-6 (IL-6). Both experimental and synthetic data were utilised to investigate the variability in IL-6 and myeloperoxidase (MPO) production and its implications for OA pathogenesis. Methods: Synovial biopsies were obtained from OA patients undergoing joint replacement surgery. FLS were isolated, cultured, and stimulated with varying concentrations of LPS and IL-6. The production of IL-6 and MPO was measured using enzyme-linked immunosorbent assays (ELISA). Synthetic data generation techniques expanded the dataset to support comprehensive statistical analyses. Results: The patterns of inflammatory responses revealed distinct patient subgroups, highlighting individual variability. The integration of synthetic data with experimental observations validated their reliability and demonstrated dose-dependent differences in IL-6 and MPO production across patients. Conclusions: The results highlighted the importance of patient-specific factors in OA inflammation and demonstrated the utility of combining experimental and synthetic data to model individual variability. The results support the development of personalised treatment strategies in OA. Future research should include larger patient datasets and an exploration of molecular mechanisms underlying these responses.